References
- Brandon, W. E. (1997). Disabled my life, the first fifty years with sickle cell disease. Philadelphia, VACS.
- Brozovic, M., Davies, S. C. and Brownell, A. I. (1987). Acute admissions of patients with sickle cell disease who live in Britain. BMJ, 294, 1206–1208.
- Fuggle, P., Shand, P. A. X., Gill, L. J. and Davies, S. C. (1996). Pain, quality of life and coping in sickle cell disease. Arch. Dis. Child, 75, 199–203.
- Ballas, S. K. (1997). Management of sickle pain. Curr. Op. in Hematol., 4, 104–111.
- Stone, P. A., MacIntyre, P. E. and Jarvis, D. A. (1993). Norpethidine toxicity and patient controlled analgesia. Brit. J. Anaes., 71, 738–740.
- Christensen, M. L., Wang, W. C., Harris, S., Eades, S. K. and Wiliams, J. A. (1996). Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. J. Ped. Hematol/Oncol., 18, 372–376.
- Griffin, T. C., McIntire, D. and Buchanan, G. R. (1994). High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N. Engl. JM, 330, 733–737.
- Platt, O. S. (1994). Easing the suffering caused by sickle cell disease. N. Engl. J. Med., 330, 783–784.
- Emre, U., Miller, S. T., Gutierez, M. et al. (1995). Effect of transfusion in acute chest syndrome in sickle cell disease. J. Pediatr., 127, 901–904.
- Bellet, P. S., Kalinyak, K. A., Shukla, R. et al. (1995). Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N. Engl. J. Med., 333, 699–703.
- Wang, W. C., Kovnar, E. H., Tonkin, I. L. et al. (1991). High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J. Pediatr., 118, 377–382.
- Adams, R. J., McKie, V. C., Carl, E. M., Nichols, F. T., Perry, R., Brook, K., McKie, K., Figueroa, R., Litaker, M., Weiner, S. and Brambilla, D. (1997). Long term stroke risk in children with sickle cell disease screened with transcranial Doppler. Annals of Neurology, 42(5), 699–704.
- Virag, R., Bachir, D., Lee, K. and Galacteros, F. (1996). Preventive treatment of priapism in sickle cell disease with oral and self intracavemous injection of etilefrine. Urol, 47, 777–781.
- Serjeant, G. R. (1992). Sickle Cell Disease. 2nd edn. Oxford, OUP.
- Davies, S. C. and Roberts-Harewood, M. (1997). Blood transfusion in sickle cell disease. Blood Reviews, 11,57–71.
- Koshy, M., Weiner, S. J., Miller, P. T. et al. (1995). Surgery and anesthesia in sickle cell disease. Blood, 88, 3676–3684.
- Kim, H. C., Dugan, N. P., Silber, J. H. et al. (1994). Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood, 83, 1136–1142.
- Porter, J. B., Alberti, D., Hassan, I. et al. (1997). Subcutaneous depot desferrioxamine; relationship of pharmacokinetics to efficacy and drug metabolism. Blood, 90(10), [Abstract 1163].
- Nokes, T. J. C., Mak, V., Roberts-Harewood, M. and Davies, S. C. (1998). Pulmonary function tests in sickle cell disease. Patients do not always deteriorate with time. B. J. Haematol., 101, (Suppl. 1), [Abstract 123].
- Miner, D. J., Jorkaksy, D. K., Perloff, L. J., Grossman, R. A. and Tomaszewski, J. E. (1987). Recurrent sickle cell nephropathy in a transplanted kidney. Am. J. Kidney Dis., 4, 306–313.
- Nokes, T. J. C., Porter, J. B., Roberts-Harewood, M. and Davies, S. C. (1997). Topical GM-CSF—a treatment for chronic sickle ulcers. B. J. Haematol., 97, (Suppl. 1), [Abstract 276]
- Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P. and Bonds, D. R. (1995). Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N. Engl. J. Med., 332, 1317–1322.
- Fruchtman, S. M., Mack, K., Kaplan, M. E., Peterson, P., Berk, P. D. et al. (1997). From efficacy to safety: a polycyth-emia vera study group report on hydroxyurea in patients with polycythemia vera. Sem. in Hem., 34(1), 17–23.
- Triadou, P., Maier-Redelsperger, M., Krishnamoorty, R. et al. (1994). Fetal hemoglobin variations following hydroxyurea treatment in patients with cyanotic congenital heart disease. Nouv. Rev. Fr. Haematol., 36, 367–372.
- Charache, S., Barton, F. B., Moore, R. D., Terrin, M. L., Steinberg, M. H. et al. (1996). Hydroxyurea and sickle cell anemia. Med., 75, 300–326.
- Ferster, A., Vermylen, C., Cornu, G., Buyse, M., Corazza, C. et al. (1996). Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood, 88, 1960–1964.
- Claster, S. and Vichinsky, E. P. (1996). First report of reversal of organ dysfunction in sickle cell anemia: by the use of hydroxyurea; splenic regeneration. Blood, 88, 1951–1953.
- Kelly, P., Kurtzberg, J., Vichinsky, E. and Lubin, B. (1997). Umbilical cord blood stern cells: application for the treatment of patients with haemoglobinopathies. J. Pediatr., 130, 695–703.
- Harris, R. E. and Joiner, C. H. (1997). Should children with hemoglobinopathies be offered unrelated-donor cord blood stem cell transplantation? J. Pediatr., 130, 689–691.